Equity · Healthcare
VOR
NASDAQVor Biopharma (VOR)
The line runs 22.28 USD on 12 August through 19.99 USD on 9 November, on a scale from 17.5 to 27.5. Days the market did not trade hold the previous close, flat.
- Market cap
- 1.2B USD
- P/E (TTM)
- 0.1
- EPS, diluted, year to Dec 2025
- −70.50 USD
- 52-week range
- 7 USD – 25.03 USD
- Avg volume
- 46.3K
- Mentions, 30 days
- 3
as of Nov 9, 2026
Have Vor Biopharma (VOR) insiders bought or sold shares recently?
In the 90 days to 10 Nov 2026, no Vor Biopharma insider bought or sold shares on the open market; all 3 Form 4 filings in that window were grants, exercises, tax withholding or transfers (SEC Form 4).
Form 4, 90 days to 10 Nov 2026, newest Form 4 filing 2 Nov 2026
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 02 Nov 2026 | Sokolove Jeremy BrettChief Medical Officer | Tax withheld | 1,917 | 37K USD |
| 02 Oct 2026 | RA CAPITAL MANAGEMENT, L.P.10% Owner | Option exercise | 500 | 6K USD |
| 24 Aug 2026 | RA CAPITAL MANAGEMENT, L.P.10% Owner | Option exercise | 1,500 | 6K USD |
Which funds hold Vor Biopharma (VOR)?
7 of the 45 institutional funds we track reported a Vor Biopharma position for the quarter ended 30 Jun 2026 — a combined 15.3M USD; the latest of those filings landed 02 Sep 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Millennium Management | Added | 428,067 | 7.9M USD | +65.5% |
| Citadel Advisors | Held (±25%) | 160,414 | 3.0M USD | +7.8% |
| Marshall Wace | Trimmed | 95,643 | 1.8M USD | −91.7% |
| D. E. Shaw & Co. | New position | 54,671 | 1.0M USD | |
| Two Sigma Investments | New position | 37,012 | 681K USD | |
| Renaissance Technologies | Trimmed | 33,011 | 608K USD | −74.4% |
| Tudor Investment Corp | Trimmed | 19,620 | 361K USD | −87.1% |
What has been filed or recorded for Vor Biopharma (VOR)?
The filings we hold for Vor Biopharma, newest first: 2 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 4 reported financial figures, the latest dated 06 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 06 Oct 2026 | Fails to deliver | Shares failed to deliver | 2,267 shares | 42K USD notional · 0.004% of shares out |
| 30 Sep 2026 | Fails to deliver | Shares failed to deliver | 436 shares | 8K USD notional · 0.001% of shares out |
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS −1.45 USD | |
| 30 Sep 2026 | Financials | Total assets | 496.3M USD | at period end |
| 30 Sep 2026 | Financials | Total equity | −137.2M USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −1.16 USD | |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −5.11 USD | |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −70.50 USD | |
| 31 Dec 2025 | Financials | Net income | −696.0M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −70.50 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −121.63 USD | |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −251.24 USD | |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −5.21 USD | |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −34.03 USD |
What is Reddit saying about Vor Biopharma (VOR)?
Reddit mentioned VOR 3 times in the 30 days to 10 November 2026, in 1 of the communities we track. All of them were scored for sentiment: 100% read bullish, 0% bearish and 0% neither. Reddit data updated 10 November 2026.
30-day window, Method
How do Reddit mentions of Vor Biopharma (VOR) compare with its price?
Share ↗
Which subreddits are talking about Vor Biopharma (VOR)?
30 days
| Community | Share | Mentions | Net sentiment |
|---|---|---|---|
| r/wallstreetbets | 100% | 3 | +0.08 |
What do people ask about Vor Biopharma (VOR)?
What did Vor Biopharma shares close at?19.99
Vor Biopharma closed at 19.99 USD on 9 Nov 2026, up 0.48% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Vor Biopharma’s market cap?1.2B
Vor Biopharma is worth 1.2B USD by market value as of 9 Nov 2026, which is the share price times the shares on issue from its SEC filings.
What is Vor Biopharma’s P/E ratio?0.1
Vor Biopharma has a price-to-earnings ratio of 0.1, as of 9 Nov 2026: the share price divided by what the company earned per share over the last four reported quarters. A higher number means the market pays more for each dollar of earnings.
Have Vor Biopharma insiders bought or sold shares recently?3 filings
In the 90 days to 10 Nov 2026, no Vor Biopharma insider bought or sold shares on the open market; all 3 Form 4 filings in that window were grants, exercises, tax withholding or transfers (SEC Form 4). See Insiders
Which funds own Vor Biopharma?7 of 45
7 of the 45 funds we track reported a Vor Biopharma position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were Millennium Management, Citadel Advisors and Marshall Wace. See Funds
When did Vor Biopharma last report earnings?−1.45
Vor Biopharma last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −1.45 USD; no next date is announced in SEC filings yet. See Filings
What is Reddit saying about Vor Biopharma?0 mentions
Vor Biopharma was mentioned 0 times in the last 7 days across the finance subreddits we track, and 3 times over the trailing 30 days. Of the 3 mentions scored for sentiment, 100% read bullish and 0% bearish. That is a social signal, not investment advice. See Reddit
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- RedditReddit ingest across the tracked finance subreddits
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings